Oramed Pharmaceuticals Inc. earnings per share and revenue
On Jan 08, 2026, ORMP reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 3 analysts forecast an EPS of 0.00 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
0.00%
Abbott Laboratories
Report Date
Jan 22, 2026 For Q4 25
Estimate
$1.51
Actual
$1.50
Surprise
-0.75%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
FAQ
What were Oramed Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Oramed Pharmaceuticals Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Oramed Pharmaceuticals Inc.'s Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Oramed Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Mar 25, 2026.
What are the forecasts for Oramed Pharmaceuticals Inc.'s next earnings report?
Based on 3
analysts, Oramed Pharmaceuticals Inc. is expected to report EPS of -- and revenue of -- for Q4 2025.